Literature DB >> 10857792

Treatment of rolling neutrophils with antineutrophil cytoplasmic antibodies causes conversion to firm integrin-mediated adhesion.

D J Radford1, C O Savage, G B Nash.   

Abstract

OBJECTIVE: The vascular lesions associated with autoimmune small-vessel vasculitis may arise from activation of circulating neutrophils by antineutrophil cytoplasmic antibodies (ANCA), resulting in increased adhesion of these neutrophils to the vessel wall. The present study examined the effects of ANCA-positive IgG (ANCA IgG), derived from patients with small-vessel vasculitis, on neutrophil adhesion.
METHODS: An in vitro, flow-based adhesion assay was used to determine the effects of ANCA IgG on neutrophils rolling on P-selectin presented by a monolayer of activated platelets. The platelets act as a surrogate vessel wall and can also support beta2 integrin-mediated immobilization of neutrophils if they are purposefully activated (e.g., by FMLP).
RESULTS: In the absence of any added agents, neutrophils rolled continuously over the platelet monolayer. Superfusion of ANCA IgG over rolling cells resulted in conversion to stationary adhesion accompanied by shape change. The ANCA-mediated response was transient, peaking at 5-6 minutes and returning to baseline by 15 minutes, even in the continued presence of ANCA. In contrast, normal (ANCA-negative) IgG and ANCA F(ab')2 fragments caused minimal conversion to stationary adhesion. Pretreatment of neutrophils with blocking antibodies directed toward Fc gamma receptor type IIA or the integrin chain CD11b completely inhibited the ANCA-mediated conversion, confirming that ANCA-mediated activation occurred through Fc gamma receptors and that neutrophil immobilization was mediated by the activated beta2 integrin (CD11b/CD18).
CONCLUSION: These findings support the concept that ANCA can directly activate neutrophils to become firmly adherent to vessel walls, where they may obstruct flow, initiate tissue damage, and contribute to pathogenesis of vasculitis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10857792     DOI: 10.1002/1529-0131(200006)43:6<1337::AID-ANR16>3.0.CO;2-M

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  31 in total

Review 1.  Immunopathological aspects of systemic vasculitis.

Authors:  I M Bajema; E C Hagen; F Ferrario; E de Heer; J A Bruijn
Journal:  Springer Semin Immunopathol       Date:  2001

2.  Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies.

Authors:  Hong Xiao; Adrian Schreiber; Peter Heeringa; Ronald J Falk; J Charles Jennette
Journal:  Am J Pathol       Date:  2007-01       Impact factor: 4.307

3.  Mechanisms of ANCA-mediated leukocyte-endothelial cell interactions in vivo.

Authors:  Sarah L Nolan; Neena Kalia; Gerard B Nash; Dia Kamel; Peter Heeringa; Caroline O S Savage
Journal:  J Am Soc Nephrol       Date:  2008-02-27       Impact factor: 10.121

4.  Sustained monocyte activation in clinical remission of systemic vasculitis.

Authors:  Agneta Wikman; Joachim Lundahl; Stefan H Jacobson
Journal:  Inflammation       Date:  2008-12       Impact factor: 4.092

Review 5.  Pathogenesis of ANCA-Associated Pulmonary Vasculitis.

Authors:  Marco A Alba; J Charles Jennette; Ronald J Falk
Journal:  Semin Respir Crit Care Med       Date:  2018-11-07       Impact factor: 3.119

Review 6.  Pathogenesis of ANCA-associated vasculitis.

Authors:  Rodrigo Cartin-Ceba; Tobias Peikert; Ulrich Specks
Journal:  Curr Rheumatol Rep       Date:  2012-12       Impact factor: 4.592

Review 7.  Endothelium-neutrophil interactions in ANCA-associated diseases.

Authors:  Lise Halbwachs; Philippe Lesavre
Journal:  J Am Soc Nephrol       Date:  2012-09       Impact factor: 10.121

Review 8.  B cell epitope specificity in ANCA-associated vasculitis: does it matter?

Authors:  Y M van der Geld; C A Stegeman; C G M Kallenberg
Journal:  Clin Exp Immunol       Date:  2004-09       Impact factor: 4.330

9.  Management of ANCA-associated vasculitis: Current trends and future prospects.

Authors:  Sally Hamour; Alan D Salama; Charles D Pusey
Journal:  Ther Clin Risk Manag       Date:  2010-06-24       Impact factor: 2.423

Review 10.  Pathophysiology of ANCA-associated small vessel vasculitis.

Authors:  Cees G M Kallenberg
Journal:  Curr Rheumatol Rep       Date:  2010-12       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.